文献速递眼底病与葡萄膜炎

女性生殖因素与渗出性年龄相关性黄斑变性风险:全国性队列研究

FEMALE REPRODUCTIVE FACTORS AND THE RISK OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A Nationwide Cohort Study.
PubMed 文献 · Retina · 2021-01-01

该研究基于韩国国民健康保险系统数据库,纳入2009年参加健康筛查和癌症筛查的1,297,388名50岁以上绝经后女性,随访至2018年。结果显示,生殖期≥40年、激素替代治疗≥5年及2–5年者的渗出性AMD风险均升高,提示终身内源性和外源性雌激素暴露增加与渗出性AMD发病率升高相关。

要点

  • 生殖期≥40年者渗出性AMD风险高于生殖期<30年者(HR 1.14,95%CI 1.01–1.31)。
  • 激素替代治疗≥5年者风险升高(HR 1.72,95%CI 1.48–2.00),2–5年者亦升高(HR 1.29,95%CI 1.09–1.52)。
  • 终身内源性和外源性雌激素暴露增加与渗出性AMD发病率升高相关。

核心结论

  • 女性生殖因素与渗出性年龄相关性黄斑变性风险相关,终身内源性和外源性雌激素暴露增加与渗出性AMD发病率升高相关。

研究设计与样本

  • 基于韩国国民健康保险系统数据库的全国性队列研究,纳入1,297,388名50岁以上绝经后女性,随访至2018年,采用多变量校正Cox比例风险模型估计风险比。

主要发现

  • 平均随访7.27年期间,4,086例新诊断为渗出性AMD。
  • 生殖期≥40年者渗出性AMD的HR为1.14(95%CI 1.01–1.31),参照为生殖期<30年者。
  • 激素替代治疗≥5年者HR为1.72(95%CI 1.48–2.00),2–5年者HR为1.29(95%CI 1.09–1.52),参照为从未接受激素替代治疗者。

关键数值与推荐

  • 生殖期≥40年相比<30年,渗出性AMD风险HR 1.14(95%CI 1.01–1.31)。
  • 激素替代治疗≥5年相比从未使用,HR 1.72(95%CI 1.48–2.00)。
  • 激素替代治疗2–5年相比从未使用,HR 1.29(95%CI 1.09–1.52)。

临床怎么用

  • 对绝经后女性评估渗出性AMD风险时,可关注生殖期长度和激素替代治疗史。
  • 对长期接受激素替代治疗或有较长生殖期的女性,可考虑加强眼底监测。

局限性

  • 生殖因素数据来自自填问卷,可能存在回忆偏倚。
  • 研究人群为韩国绝经后女性,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association between female reproductive factors and the incidence of exudative age-related macular degeneration (AMD). METHODS: A total of 1,297,388 postmenopausal women over 50 years of age who participated in both national health screening and cancer screening in 2009 were identified using the Korea National Health Insurance System database. Data on female reproductive factors were collected using a self-administered questionnaire. Patients were followed up until 2018, and the incident cases of exudative AMD were identified. The hazard ratios and 95% confidence intervals for exudative AMD were estimated using the multivariable-adjusted Cox proportional hazard model. RESULTS: During a mean follow-up of 7.27 years, 4,086 patients were newly diagnosed with exudative AMD. The hazard ratio (95% confidence intervals) for exudative AMD was 1.14 (1.01-1.31) for a reproductive period ≥40 years compared with a reproductive period <30 years, 1.72 (1.48-2.00) for patients with ≥5 years of hormone replacement therapy, and 1.29 (1.09-1.52) for those with 2 to 5 years of hormone replacement therapy compared with those who never underwent hormone replacement therapy. CONCLUSION: Female reproductive factors were associated with the risk of exudative AMD. Greater lifetime exposure to endogenous and exogenous estrogen was associated with a higher incidence of exudative AMD.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Hwang S, Kang SW, Han J, et al. FEMALE REPRODUCTIVE FACTORS AND THE RISK OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A Nationwide Cohort Study. Retina. 2021. PMID: 33675332. doi:10.1097/IAE.0000000000003164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。